title: Clinical course of central neurocytoma with malignant transformation-an indication for craniospinal irradiation.
abstract: Central neurocytoma is generally considered to be a benign tumor and the literature suggests that a cure may be attained by surgery ± adjuvant focal irradiation. However, there is a need for change in the therapeutic strategy for the subgroup of patients with aggressive central neurocytoma. An example case is presented and the literature on central neurocytoma cases with malignant features and dissemination via the cerebrospinal fluid is reviewed and the radiotherapeutic strategies available for central neurocytoma treatment is discussed. Nineteen cases including the present report with a malignant course and cerebrospinal fluid dissemination have been described to date, most of them involving an elevated MIB-1 labeling index. Our case exhibited atypical central neurocytoma with an initially elevated MIB-1 labeling index (25-30 %). The primary treatment included surgery and focal radiotherapy. Three years later the disease had disseminated throughout the craniospinal axis. A good tumor response and symptom relief were achieved with repeated radiation and temozolomide chemotherapy. Central neurocytoma with an initially high proliferation activity has a high tendency to spread via the cerebrospinal fluid. The chemo- and radiosensitivity of the tumor suggest a more aggressive adjuvant therapy approach. Cases with a potential for malignant transformation should be identified and treated appropriately, including irradiation of the entire neuroaxis and adjuvant chemotherapy may be considered.
authors.affiliation: Department of Oncotherapy, University of Szeged, Albert Szent-Györgyi Clinical Center, 6720, Szeged, Korányi fasor 12, Hungary, mozespetra@gmail.com.
authors.forename: Petra
authors.initials: P
authors.lastname: Mozes
authors.forename: Erika
authors.initials: E
authors.lastname: Szanto
authors.forename: Laszlo
authors.initials: L
authors.lastname: Tiszlavicz
authors.forename: Pal
authors.initials: P
authors.lastname: Barzo
authors.forename: Adrienne
authors.initials: A
authors.lastname: Cserhati
authors.forename: Emese
authors.initials: E
authors.lastname: Fodor
authors.forename: Katalin
authors.initials: K
authors.lastname: Hideghety
mesh_terms: D000328:Adult; D001932:Brain Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology* / Q000532:radiotherapy; D002471:Cell Transformation, Neoplastic / Q000378:metabolism / Q000473:pathology*; D002555:Cerebrospinal Fluid / Q000378:metabolism; D017024:Chemotherapy, Adjuvant / Q000379:methods; D002675:Child, Preschool; D061888:Craniospinal Irradiation / Q000379:methods; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D006801:Humans; D019394:Ki-67 Antigen / Q000378:metabolism; D008279:Magnetic Resonance Imaging / Q000379:methods; D008297:Male; D008875:Middle Aged; D018306:Neurocytoma / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology* / Q000532:radiotherapy; D018714:Radiotherapy, Adjuvant / Q000379:methods; D000077204:Temozolomide; D055815:Young Adult
chemical_list: D019394:Ki-67 Antigen; D003606:Dacarbazine; D000077204:Temozolomide